Last reviewed · How we verify
Placebo matched to FTC/TDF
This is a placebo control arm matched to the active combination of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), containing no active antiretroviral agents.
This is a placebo control arm matched to the active combination of emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), containing no active antiretroviral agents. Used for Control arm in HIV prevention or treatment trials (Phase 3).
At a glance
| Generic name | Placebo matched to FTC/TDF |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
As a placebo, this formulation contains inert ingredients designed to match the appearance and administration schedule of FTC/TDF without providing any antiretroviral activity. FTC/TDF itself works by inhibiting reverse transcriptase in HIV, but the placebo arm serves as a control comparator in clinical trials to assess the efficacy and safety of the active drug.
Approved indications
- Control arm in HIV prevention or treatment trials (Phase 3)
Common side effects
Key clinical trials
- A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062) (PHASE2, PHASE3)
- A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010) (PHASE3)
- A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011) (PHASE3)
- Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020) (PHASE3)
- Dose Ranging, Switch Study of Islatravir (MK-8591) and Ulonivirine (MK-8507) Once-Weekly in Virologically-Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) [MK-8591-013] (PHASE2)
- Study of Oral Weekly GS-1720 and GS-4182 Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed (PHASE2, PHASE3)
- Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection (PHASE3)
- Study of Oral Weekly GS-1720 and GS-4182 Compared With Biktarvy in People With HIV-1 Who Have Not Been Treated (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matched to FTC/TDF CI brief — competitive landscape report
- Placebo matched to FTC/TDF updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI